> Detailanzeige

Siehl, Jan M.; Thiel, Eckhard; Schmittel, Alexander; Hütter, Gero; Deckert, Peter M.; Szelényi, Hubert; Keilholz, Ulrich

Ifosfamide/liposomal daunorubicin is a well tolerated and active first‐line chemotherapy regimen in advanced soft tissue sarcoma : Results of a Phase II study : Results of a Phase II study

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Ifosfamide/liposomal daunorubicin is a well tolerated and active first‐line chemotherapy regimen in advanced soft tissue sarcoma : Results of a Phase II study : Results of a Phase II study
  • Beteiligte: Siehl, Jan M.; Thiel, Eckhard; Schmittel, Alexander; Hütter, Gero; Deckert, Peter M.; Szelényi, Hubert; Keilholz, Ulrich
  • Erschienen: Wiley, 2005
  • Erschienen in: Cancer
  • Sprache: Englisch
  • DOI: 10.1002/cncr.21211
  • ISSN: 0008-543X; 1097-0142
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>BACKGROUND</jats:title><jats:p>The anthracycline/ifosfamide combination is the most effective chemotherapy in soft tissue sarcoma. To improve the tolerability and potential efficacy of this combination, the authors combined a moderate dose of continuous infusion ifosfamide with liposomal daunorubicin (L‐Dauno).</jats:p></jats:sec><jats:sec><jats:title>METHODS</jats:title><jats:p>In a single‐arm, Phase II study, 40 patients with a median age of 57 years (range, 19–78 years) were enrolled. Of these, 35 patients were treated with first‐line chemotherapy. The treatment regimen was comprised of ifosfamide at a dose of 5 g/m<jats:sup>2</jats:sup> over 24 hours and L‐Dauno at a dose of 100 mg/m<jats:sup>2</jats:sup> every 4 weeks with granulocyte–colony‐stimulating factor support.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>Eleven (31%) of 35 anthracycline/ifosfamide‐naive patients achieved a partial/complete response, 6 patients (17%) had stable disease, and 13 patients (37%) had disease progression. Three patients were not evaluable, and there were two intermittent deaths. The median time to disease progression was 6 months, the median overall survival was 14 months, and the median time to treatment failure was 15 months. Toxicity was tolerable.</jats:p></jats:sec><jats:sec><jats:title>CONCLUSIONS</jats:title><jats:p>The combination of Ifosfamide and L‐Dauno was found to be a highly active chemotherapy regimen for first‐line treatment of soft tissue sarcoma. Therefore, we believe randomized studies with this regimen are warranted. Cancer 2005. © 2005 American Cancer Society.</jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang